P1639 Fecal Microbiota Transplant for Treatment of Refractory C. difficile Colitis: Long-Term Follow-Up of 58 Patients

Daniel Greenwald, MD
Daniel Greenwald, MD

Author insight from Daniel Greenwald, MD, Tarun Patel, MD and Amy Barto, MD, Lahey Hospital & Medical Center

What’s new here and important for clinicians?
Fecal microbiota transplant (FMT) is a viable treatment option for C. difficile colitis infection that is recurrent or refractory to standard antibiotic therapy. Our research supports the efficacy of FMT as a treatment associated with a 91% primary response rate at three months post procedure, and a sustained response for 80% of our 58 patients at 18 months of follow up.

Tarun Patel. MD
Tarun Patel. MD
Amy Barto, MD
Amy Barto, MD

What do patients need to know?
Patients should know that FMT is a well established and effective option for treating C. difficile colitis infection that is recurrent or refractory to standard antibiotic therapy. It is a safe therapy and associated with good long term outcomes based on our data. FMT has been used for treatment of C. difficile colitis at least as early as 1958, and in fact stool transplant has been documented dating back thousands of years. Patients should also recognize that probiotic therapy as an adjunct to FMT may be associated with better outcomes, as well as avoiding antibiotics unless absolutely necessary post-FMT.

Read abstract

Author Contact
Daniel Greenwald, M, Lahey Hospital & Medical Center

Related Abstracts

Oral 72 Fresh, Frozen, or Lyophilized Fecal Microbiota Transplantation (FMT) for Multiple Recurrent C. difficile Infection (CDI)
Oral 71 C. difficile Associated Risk of Death Score (CARDS): A Novel Risk Score to Predict Mortality Among Hospitalized Patients With C. difficile Infection
P454 Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients With Inflammatory Bowel Disease


Media Interview Requests:

Press room and video recording facilities will be available onsite. To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000.